Quizartinib
Author: Rachael Lloyd
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Quizartinib (Daiichi Sankyo) is an oral multi-tyrosine kinase inhibitor of the platelet-derived growth factor receptor, KIT/c-KIT, and FMS-like tyrosine kinase 3 (FLT3) receptor. Mutations in the FLT3 gene are found in more than 30% of patients with acute myeloid leukemia and result in disruption of the secondary structure of the tyrosine kinase, which often leads to constitutive receptor activation and unregulated cell signaling. Quizartinib exerts its anti-tumor activity by binding to the FLT3 receptor and inhibiting phosphorylation, resulting in the inhibition of receptor activation.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 quizartinib : Acute myeloid leukemia (AML)
LIST OF FIGURES
10 Figure 1: quizartinib for acute myeloid leukemia – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of quizartinib for acute myeloid leukemia
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of quizartinib for acute myeloid leukemia
LIST OF TABLES
5 Table 1: quizartinib drug profile
7 Table 2: quizartinib Phase III trials in acute myeloid leukemia
9 Table 3: quizartinib Phase II data in acute myeloid leukemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Rydapt 
Sign up to the